Factors affecting time delay to treatment in a tuberculosis control programme in a sub-Saharan African country: the experience of The Gambia.

Christian Lienhardt(Institut de Recherche pour le Développement), Keith P. W. J. McAdam(London School of Hygiene & Tropical Medicine), Kebba Manneh, Dale M. Needham, Jane Rowley(Institut de Recherche pour le Développement), Paul Milligan(MRC Unit the Gambia), George Lahai(MRC Unit the Gambia)
PubMed
March 1, 2001
Cited by 176

Related Papers

Bulletin of the World Health Organization
|Bulletin of the World Health Organization|2001|7.2k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
|Clinical Infectious Diseases|2016|1.5k
An Official American Thoracic Society Clinical Practice Guideline: The Diagnosis of Intensive Care Unit–acquired Weakness in Adults
|American Journal of Respiratory and Critical Care Medicine|2014|531
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
|The Lancet|2001|528